Newsfeeds - Spark Newswire - Page 3

Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Read More

2 minute read

Gain Therapeutics Outlines Key Objectives For 2022 Following Inaugural R&D Day

By Benzinga Newsdesk

Today, 10:10 AM

Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a biotechnology company transforming and accelerating drug discovery with structurally targeted allosteric regulators identified with

Read More

3 minute read

52 Biggest Movers From Yesterday

Today, 10:10 AM

Gainers ION Geophysical Corporation (NYSE: IO) shares surged 29.8% to settle at $0.5969.

Read More

3 minute read

34 Stocks Moving In Tuesday’s Mid-Day Session

Today, 10:10 AM

Gainers Biofrontera Inc. (NASDAQ: BFRI) shares climbed 30.7% to $4.4095 after the company provided an update on patient recruitment for the Phase III study for the treatment of sBCC with Ameluz-PDT.

Read More

25 minute read

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

Today, 10:10 AM

During Friday's session, 445 companies made new 52-week lows.

Read More

4 minute read

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

Today, 10:10 AM

On Wednesday, 41 stocks made new 52-week lows.

Read More

6 minute read

Stocks That Hit 52-Week Lows On Tuesday

By Benzinga Insights

Today, 10:10 AM

During Tuesday's morning trading, 87 companies set new 52-week lows.

Read More

1 minute read

Trading Ideas

Watching Gain Therapeutics, Esports Entertainment; Traders Circulate TipRanks Report ‘2 “Strong Buy” Stocks Under $10 With Triple-Digit Upside’

By Benzinga Newsdesk

Today, 10:10 AM

https://blog.tipranks.com/2-strong-buy-stocks-under-10-with-triple-digit-upside/

Read More

2 minute read

Gain Therapeutics Stock Surges On Positive Preclinical Readout For Neurodegenerative Disease Drugs

By Shanthi Rexaline

Today, 10:10 AM

Gain Therapeutics, Inc. (NASDAQ: GANX) shares were trading higher Wednesday after the company presented positive data on two of its lead compounds.

Read More

9 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For November 3, 2021

By Benzinga Insights

Today, 10:10 AM

Read More

1 minute read

B. Riley Securities Initiates Coverage On Gain Therapeutics with Buy Rating, Announces Price Target of $21

By Benzinga Newsdesk

Today, 10:10 AM

B. Riley Securities analyst Mayank Mamtani initiates coverage on Gain Therapeutics (NASDAQ:GANX) with a Buy rating and announces Price Target of $21.